Non-alcoholic fatty liver disease(NAFLD) has become one of the most prevalent chronic liver diseases worldwide, with its incidence rising rapidly alongside the increasing prevalence of obesity and metabolic syndrome. At present, the treatment of NAFLD mainly relies on lifestyle intervention, but there is a lack of specific drugs. With in-depth research into the pathophysiological mechanisms of NAFLD, multiple drugs target metabolic disorders, inflammation, and fibrosis have become a hot topic. This article reviewed the latest advancements in NAFLD drug development, statistically analyzed global research trends and therapeutic hotspots, focused on introducing the clinical trial outcomes of metabolic modulators, anti-inflammatory or anti-fibrotic agents, and emerging targets, and discussed the future directions in this field.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |